slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 96,741
Current window 86,851-86,880
Pages 3,225
Rows per page 30
Component
86,851-86,880 of 96,741
04
The slide uses a split-view layout to contrast the company's reach across brands and retailers.Advantage Solutions | Investor Presentation Deck | 25 slides · Advantage Solutions
Pitch deck Investor relations 1 hit
06
The slide uses a donut chart to visualize the revenue split between the two segments.Advantage Solutions | Investor Presentation Deck | 25 slides · Advantage Solutions
Pitch deck Investor relations 1 hit
09
The slide uses a dual-table layout to segment clients into 'Brands' and 'Retailers', emphasizing the longevity of these partnerships.Advantage Solutions | Investor Presentation Deck | 25 slides · Advantage Solutions
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
16
The slide uses a four-column layout to categorize strategic financial priorities.Advantage Solutions | Investor Presentation Deck | 25 slides · Advantage Solutions
Pitch deck Investor relations 1 hit
09
The slide uses a stacked bar chart to visualize the response rates and a table to detail specific IWG criteria outcomes.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · Comparative Analysis1 hit
08
The slide uses a timeline framework to establish credibility and future-looking innovation.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Complication1 hit
18
AstraZeneca | Investor Event Presentation Deck | 42 slidesAstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Quick Win Big Bet1 hit
22
The slide uses a standard Kaplan-Meier survival analysis framework common in oncology clinical trials.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Before After1 hit
23
Clinical trial data visualization showing hazard ratios and median PFS.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Before After1 hit
24
Clinical trial data visualization showing progression-free survival (PFS) curves with associated hazard ratios and event counts.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Before After1 hit
25
The slide uses a split-panel design to compare two patient cohorts (ESR1m detectable vs not detectable).AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Before After1 hit
29
The slide summarizes the primary outcomes of the SERENA-2 trial, confirming PFS benefits and safety, and mentions ongoing Phase III trials (SERENA-4 and SERENA-6).AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & Proof1 hit
31
Includes Kaplan-Meier survival curve and key efficacy metrics.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
36
Uses a before-after-bridge structure to frame the problem (poor outcomes) and the solution (Capivasertib).AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Confession1 hit
37
The slide uses a stacked bar chart to show market share evolution over three quarters and bulleted lists to summarize clinical trial outcomes.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
07
Includes a callout regarding architect popularity and a note on the replacement cycle of existing decks.Azek | Investor Presentation Deck | 37 slides · Azek
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
Uses a before-and-after visual comparison for decking and specific conversion percentages for trim and railing.Azek | Investor Presentation Deck | 37 slides · Azek
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Includes a central hub-and-spoke diagram for core values and a sidebar for 'Full-Circle' ESG ambitions.Azek | Investor Presentation Deck | 37 slides · Azek
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
22
Includes specific cost breakdown for a 16' x 20' deck scenario.Azek | Investor Presentation Deck | 37 slides · Azek
Pitch deck Investor relations Beat · Product1 hit
26
The slide uses a grid-based layout to categorize product offerings.Azek | Investor Presentation Deck | 37 slides · Azek
Pitch deck Investor relations Beat · Product1 hit
12
The slide uses a numbered list format to break down value drivers.Proterra | Investor Presentation Deck | 28 slides · Proterra
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
The slide uses a before-and-after framing to demonstrate the value proposition of the software.Proterra | Investor Presentation Deck | 28 slides · Proterra
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
The slide uses donut charts to visualize the split between 3rd party suppliers and vertically integrated manufacturing for specific vehicle types.Proterra | Investor Presentation Deck | 28 slides · Proterra
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
14
The chart illustrates a worsening of blood pressure in the placebo group compared to the treatment group.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Before After1 hit
19
The slide highlights the failure of Study 0169 and the subsequent early termination of Study 0170.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
25
Uses a visual comparison to explain the biological mechanism of action.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
26
The slide highlights the MSA subgroup with a blue box, suggesting a focus on this specific finding.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations Beat · KPI Overview1 hit
37
The slide provides a summary of patient characteristics to demonstrate baseline comparability.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
40
The chart uses a forest plot format to visualize confidence intervals for multiple clinical endpoints.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
42
The slide includes a footnote defining abbreviations and study parameters.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit